JAZZ vs TECH · P/E 1988, rev $4.07B vs P/E 65, rev $1.22B
Jazz Pharmaceuticals PLC (JAZZ) versus Bio-Techne Corp (TECH) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
Bio-Techne Corp (TECH) is a biotechnology company listed on US.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
Latest reported TECH revenue for 2025-06-30 was $1.22B. Net income was $73.4M. Revenue was up 5.2% from 2024-06-30 to 2025-06-30. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. TECH currently screens at market cap $8.49B and trailing P/E 65.2.
Not investment advice. Open the JAZZ and TECH stock pages for the full models.
Not investment advice.